



October 7, 2026

Company Name: GNI Group Ltd.
Representative: Director, Representative Executive Officer,
President and CEO
Ying Luo, PhD
(Security Code: 2160, TSE Growth)
Contact Person: Executive Officer, CSO
Takuya Kaneko
(TEL. 03-6214-3600)

**From the Growth Market to TOPIX —
GNI Group Newly Selected in the First Periodic Review Following TOPIX Reform**

GNI Group Ltd. (TSE: 2160, the “Company”) is pleased to announce that its shares have been selected for inclusion in TOPIX (Tokyo Stock Price Index), calculated and published by JPX Market Innovation & Research, Inc. The Company’s shares are scheduled to be included in TOPIX effective October 30, 2026.

Newly Selected from the Growth Market Following TOPIX Reform

TOPIX is one of Japan’s leading stock market indices and is widely used by institutional investors in Japan and overseas as a benchmark for asset management.

Under the second phase of the TOPIX reform, with the first periodic review scheduled to take effect in October 2026, the constituent selection framework will be revised to introduce periodic reviews based on criteria including liquidity and free-float-adjusted market capitalization. Eligible companies will be selected from across all three TSE market segments: Prime, Standard and Growth.

Becoming a TOPIX Investment Target with Approximately JPY 140 Trillion in Linked Assets

According to “JPX Report 2026” published by Japan Exchange Group, Inc., assets under management linked to TOPIX amount to approximately JPY 140 trillion.

The Company believes that its inclusion in TOPIX will have the following key implications:

1. **Diversification and Greater Stability of the Shareholder Base**
As a TOPIX constituent, the Company’s shares will become an investment target for ETFs, index funds and other investment vehicles designed to track TOPIX. Continued holdings by such index-linked investment strategies are expected to contribute to further diversification and greater stability of the Company’s

shareholder base.

2. **Expanded Investment and Research Opportunities Among Institutional Investors in Japan and Overseas**
TOPIX is widely used by institutional investors in Japan and overseas as a benchmark for evaluating investment performance. Inclusion in TOPIX is expected to broaden opportunities for the Company to be considered as an investment and research target by a wider range of investors, including institutional investors with a medium- to long-term investment horizon.
3. **Enhanced Recognition in Domestic and Global Capital Markets**
Inclusion in one of Japan's leading stock market indices is also expected to create further opportunities for market participants in Japan and overseas to gain a deeper understanding of the GNI Group's business platform and growth strategy.

Dr. Ying Luo, Director, Representative Executive Officer, President and CEO of GNI Group Ltd., commented:

“We view the selection of GNI Group as a new TOPIX constituent from the Growth Market in the first periodic review under the second phase of the TOPIX reform as highly significant.

In July 2026, we completed the acquisition of AYUMI Pharmaceutical, whose product portfolio includes CALONAL®, and established the strong commercial platform in Japan that we had long sought to build. Today, we have grown into a global healthcare group with business and R&D operations spanning Japan, China, the United States and Australia.

We see our inclusion in TOPIX as a new opportunity for a broader range of investors in Japan and overseas to learn more about GNI Group. As a global biopharmaceutical company, we will continue to pursue further business growth and sustainable enhancement of corporate value.”

About GNI Group

GNI Group is a global biopharmaceutical company headquartered in Japan, with operations across Japan, China, the United States and Australia. The Group operates an integrated business platform spanning drug discovery, pharmaceutical development and commercialization, as well as medtech.

Through its proprietary drug discovery platform and innovative Targeted Protein Degradation (TPD) technology, the Group has established an integrated in-house capability extending from innovative drug discovery and basic research through global clinical development.

Its pipeline covers a broad range of therapeutic areas, including fibrosis, oncology, inflammatory diseases and pain. Key development programs include F351, a drug candidate for liver fibrosis caused by chronic hepatitis B, an indication for which no effective treatment is currently available.

The Group has also established a robust next-generation business platform encompassing integrated in-house manufacturing capabilities from active pharmaceutical ingredients (APIs) through finished products, a strong commercial network supported by its own medical representatives (MRs) covering healthcare institutions, and contract manufacturing services.

For more information about GNI Group: <https://www.gnipharma.com/>